{"id":"NCT00624819","sponsor":"GlaxoSmithKline","briefTitle":"Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine","officialTitle":"Long-term Follow-up Study to Assess Antibody Persistence in Children Previously Vaccinated With Four Doses of Pneumococcal Conjugate Vaccine in Primary Vaccination Study (105553) and Booster Vaccination Study (107046)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03-03","primaryCompletion":"2008-06-02","completion":"2008-06-02","firstPosted":"2008-02-27","resultsPosted":"2020-03-18","lastUpdate":"2021-01-27"},"enrollment":524,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal","Streptococcus Pneumoniae Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"GSK1024805A","otherNames":["Synflorix"]},{"type":"BIOLOGICAL","name":"Prevenar","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix hexa","otherNames":[]},{"type":"BIOLOGICAL","name":"Havrix","otherNames":[]},{"type":"BIOLOGICAL","name":"Varilrix","otherNames":[]}],"arms":[{"label":"Synflorix + Infanrix + Havrix and/or Varilrix Group","type":"EXPERIMENTAL"},{"label":"Prevenar + Infanrix + Havrix and/or Varilrix Group","type":"ACTIVE_COMPARATOR"},{"label":"Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix","type":"EXPERIMENTAL"},{"label":"Unprimed Group","type":"EXPERIMENTAL"}],"summary":"This protocol posting deals with objectives \\& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who received previously 4 doses of pneumococcal conjugate vaccine. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307554). This Protocol posting has been updated in order to comply with the FDA AA (Sep 2007).","primaryOutcome":{"measure":"Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (â‰¥) the Cut-off [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]","timeFrame":"At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)","effectByArm":[{"arm":"Synflorix + Infanrix + Havrix and/or Varilrix Group","deltaMin":372,"sd":null},{"arm":"Prevenar + Infanrix + Havrix and/or Varilrix Group","deltaMin":7,"sd":null},{"arm":"Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix","deltaMin":99,"sd":null}],"pValues":[]},"eligibility":{"minAge":"28 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":6,"countries":["Poland"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":391},"commonTop":["Pain","Redness","Swelling","Drowsiness","Irritability"]}}